This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yamashita, T. Articles by Wang, X. W. Search for Related Content PubMed PubMed Citation Articles by Yamashita, T. Articles by Wang, X. W.

Activation of Hepatic Stem Cell Marker EpCAM by Wnt–ß-Catenin Signaling in Hepatocellular Carcinoma

Liver Carcinogenesis Section, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland

Requests for reprints: Xin Wei Wang, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, Room 3044A, MSC 4258, Bethesda, MD 20892-4255. Phone: 301-496-2099; Fax: 301-496-0497; E-mail: xw3u{at}nih.gov.

The heterogeneous nature of hepatocellular carcinoma (HCC) and the lack of appropriate biomarkers have hampered patient prognosis and treatment stratification. Using a gene expression profiling approach, we recently identified a novel prognostic HCC subtype that resembles hepatic progenitor cells with the activation of stem cell markers and Wnt–ß-catenin signaling, based on EpCAM (epithelial cell adhesion molecule, a hepatic stem cell marker) expression. In this study, we investigated whether the activation of the Wnt–ß-catenin pathway regulates EpCAM expression. We found that nuclear accumulation of ß-catenin induced, whereas the degradation of ß-catenin or inhibition of Tcf/ß-catenin complex formation reduced EpCAM gene expression in cultured normal human hepatocytes and HCC cell lines. We identified two Tcf binding elements in the EpCAM promoter that specifically bound to Tcf-4 in an electrophoretic mobility shift assay. EpCAM promoter luciferase activity was down-regulated by the degradation of ß-catenin or inhibition of Tcf/ß-catenin complex formation. Furthermore, we found that EpCAM-positive HCC is much more sensitive to Tcf/ß-catenin binding inhibitors than EpCAM-negative HCC in vitro. Taken together, our data indicate that EpCAM is a Wnt–ß-catenin signaling target gene and may be used to facilitate HCC prognosis by enabling effective stratification of patients with predicted pharmacologic responses to Wnt–ß-catenin signaling antagonists. [Cancer Res 2007;67(22):10831–9]

This article has been cited by other articles:

				M. Munz, P. A. Baeuerle, and O. Gires The Emerging Role of EpCAM in Cancer and Stem Cell Signaling Cancer Res., July 15, 2009; 69(14): 5627 - 5629. [Abstract] [Full Text] [PDF]

				M. Okabe, Y. Tsukahara, M. Tanaka, K. Suzuki, S. Saito, Y. Kamiya, T. Tsujimura, K. Nakamura, and A. Miyajima Potential hepatic stem cells reside in EpCAM+ cells of normal and injured mouse liver Development, June 1, 2009; 136(11): 1951 - 1960. [Abstract] [Full Text] [PDF]

				F. Dong, A. S. Budhu, and X. W. Wang Translating the Metastasis Paradigm from Scientific Theory to Clinical Oncology Clin. Cancer Res., April 15, 2009; 15(8): 2588 - 2593. [Abstract] [Full Text] [PDF]

				T. Yamashita, M. Forgues, W. Wang, J. W. Kim, Q. Ye, H. Jia, A. Budhu, K. A. Zanetti, Y. Chen, L.-X. Qin, et al. EpCAM and {alpha}-Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular Carcinoma Cancer Res., March 1, 2008; 68(5): 1451 - 1461. [Abstract] [Full Text] [PDF]